Akari Therapeutics, Plc
AKTX
$3.06
-$2.09-40.58%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -29.76% | 15.56% | 9.42% | -26.90% | 18.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.87% | 20.09% | -43.85% | -41.14% | -15.62% |
| Operating Income | 24.87% | -20.09% | 43.85% | 41.14% | 15.62% |
| Income Before Tax | -38.20% | -158.65% | 74.93% | 33.44% | 8.84% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -40.46% | -121.07% | 74.93% | 33.44% | 8.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.46% | -121.07% | 74.93% | 33.44% | 8.84% |
| EBIT | 24.87% | -20.09% | 43.85% | 41.14% | 15.62% |
| EBITDA | 24.93% | -19.90% | 43.92% | 41.07% | 15.62% |
| EPS Basic | 36.90% | 17.48% | 92.50% | 83.60% | 79.34% |
| Normalized Basic EPS | 51.42% | 72.49% | 83.70% | 83.36% | 84.72% |
| EPS Diluted | 36.90% | 17.48% | 92.50% | 83.60% | 79.34% |
| Normalized Diluted EPS | 51.42% | 72.49% | 83.70% | 83.36% | 84.72% |
| Average Basic Shares Outstanding | 122.61% | 167.91% | 234.10% | 305.71% | 341.09% |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |